阅读说明：本技术 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 (Application of kelimycin and pharmaceutically acceptable salt thereof in preparing medicaments for treating and/or preventing tumors ) 是由 姜恩鸿 夏明钰 姜勋雷 姜勋东 于 2018-04-05 设计创作，主要内容包括：本发明提供了可利霉素及其药学上可接受的盐在制备治疗肿瘤药物方面的应用。所述的可利霉素及其药学上可接受的盐对乳腺癌、肝癌、肺癌、肾癌、脑瘤、宫颈癌、前列腺癌、胰腺癌、食管癌、胃腺癌、结肠癌、淋巴瘤或白血病等多种肿瘤具有较好的疗效,尤其是对人乳腺癌细胞MCF-7及MDA-MB-231,人肝癌细胞HepG2,人非小细胞肺癌细胞A549,人大细胞肺癌H460及H1299,人肾透明细胞腺癌细胞786-O,人肾细胞腺癌细胞769-P,人胶质瘤细胞U251等的生长均有明显的抑制作用。(The invention provides an application of kelimycin and pharmaceutically acceptable salts thereof in preparing a medicament for treating tumors. The colimycin and the pharmaceutically acceptable salt thereof have good curative effects on various tumors such as breast cancer, liver cancer, lung cancer, kidney cancer, brain tumor, cervical cancer, prostatic cancer, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, colon cancer, lymphoma or leukemia, and especially have obvious inhibition effects on the growth of human breast cancer cells MCF-7 and MDA-MB-231, human liver cancer cells HepG2, human non-small cell lung cancer cells A549, human large cell lung cancer cells H460 and H1299, human kidney clear cell adenocarcinoma cells 786-O, human kidney cell adenocarcinoma cells 769-P, human glioma cells U251 and the like.)

The application of the kelimycin and the pharmaceutically acceptable salt thereof in preparing the medicaments for treating and/or preventing tumors.

The use of claim 1, wherein the tumor comprises a solid tumor and a non-solid tumor.

The use of claim 2, wherein said solid tumors comprise benign solid tumors and malignant solid tumors; the non-solid tumor is lymphoma or leukemia.

The use of claim 3, wherein the malignant solid tumor is breast cancer, liver cancer, lung cancer, kidney cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, stomach cancer or colon cancer;

preferably, the brain tumor is glioma or meningioma, and the gastric cancer is gastric adenocarcinoma.

The use of any one of claims 1 to 4, wherein the medicament is a variety of dosage forms prepared from the active ingredients of the.

The use of any one of claims 1 to 4, wherein the medicament is a variety of dosage forms prepared from the kelimycin and pharmaceutically acceptable salts thereof, the antineoplastic medicament and pharmaceutically acceptable auxiliary materials.

The use according to any one of claims 1 to 4, wherein the medicament is a combination of a first agent comprising a calicheamicin and pharmaceutically acceptable salts thereof and a second agent comprising an antineoplastic agent.

The use according to claim 6 or 7, wherein the antineoplastic drug is a chemotherapeutic, radiotherapeutic, targeted therapeutic and/or immunotherapeutic drug.

The use according to claim 5 or 6, wherein the dose of the medicament is 5 to 1500 mg; preferably 50-1000 mg; more preferably 100 to 400 mg.

The use of claim 5 or 6, wherein the first agent is administered in an amount of 5 to 1500 mg; preferably 50-1000 mg; more preferably 100 to 400 mg.